Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00390676
Status:
COMPLETED
Last Update Posted:
2010-12-28
First Post:
2006-10-18
Brief Title:
A Study of ADH 1 in Combination With Carboplatin or Docetaxel or Capecitabine
Sponsor:
Adherex Technologies Inc
Organization:
Adherex Technologies Inc
Study Overview
Official Title:
A Phase 1 Multicenter Dose-Escalation Study to Investigate the Safety and Tolerability of ADH-1 in Combination With 1 Carboplatin or 2 Docetaxel or 3 Capecitabine in Subjects With N-Cadherin Positive Advanced Solid Tumors Adherex Protocol Number AHX-01-006
Status:
COMPLETED
Status Verified Date:
2010-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
N-cadherin a protein involved in blood vessel cell binding is increased as cancer progresses and is on the surface of many tumor cells ADH-1 blocks N-cadherin This study will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and docetaxel or ADH-1 and capecitabine in subjects with specific incurable solid tumors with a protein biomarker called N-cadherin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None